Learn more about treatment with PIQRAY.
For US residents only.
There is likely no shortage of tests in your life right now. However, getting an in-depth look at your HR+, HER2- metastatic breast cancer (mBC) and whether you have the PIK3CA mutation will help you and your doctor make the right treatment decision for you. It starts with asking your doctor for testing now, so you can be ready at progression. Our doctor discussion guide can help. Remember: Test to see if you have a mutation. Know your mutation status. Be empowered to choose a treatment that goes right at it.*
About 40% of all people with HR+, HER2- metastatic breast cancer have a PIK3CA mutation.
If you test positive for a PIK3CA mutation and have progressed on or after hormone therapy, you and your doctor can consider PIQRAY® (alpelisib) tablets.
To determine your PIK3CA mutation status, your doctor will test your breast cancer for an abnormal PIK3CA gene. Here’s how the process works.
Who can request it: PIK3CA mutations can only be detected through a specific genomic test ordered by your doctor.
How to request it: Even if you’ve had genetic testing done before, you’ll need to ask specifically for a PIK3CA mutation test.
How the test is performed: PIK3CA mutations can be detected in tissue or plasma specimens.1 Your doctor will send a tissue or blood sample (to get a plasma specimen). If you’ve had a biopsy done before, ask your doctor if your tissue is still viable for PIK3CA gene mutation testing. If you do not, your doctor may start with a blood test. If no mutation is found in the plasma specimen, ask your doctor to test your tissue to confirm.
By understanding your specific cancer type and PIK3CA mutation status, you can be your own best advocate and an active member of your health care team. Start a conversation with your doctor about PIK3CA mutation testing to be prepared for your next treatment. Learn tips for talking to your doctor with our helpful guide.